Ingrid J G Burvenich1, Sagun Parakh2, Hui K Gan2, Fook-Thean Lee3, Nancy Guo3, Angela Rigopoulos3, Sze-Ting Lee4, Sylvia Gong5, Graeme J O'Keefe6, Henri Tochon-Danguy5, Masakatsu Kotsuma7, Jun Hasegawa8, Giorgio Senaldi9, Andrew M Scott10. 1. Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia School of Cancer Medicine, La Trobe University, Melbourne, Australia. 2. Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia School of Cancer Medicine, La Trobe University, Melbourne, Australia Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia. 3. Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia. 4. Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia. 5. Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia. 6. Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia. 7. Translational Medicine and Clinical Pharmacology Department, Daiichi-Sankyo Co., Ltd., Tokyo, Japan. 8. Biologics Pharmacology Research Laboratories, Daiichi-Sankyo Co., Ltd., Tokyo, Japan. 9. Department of Translational Medicine and Clinical Pharmacology, Daiichi-Sankyo Pharma Development, Edison, New Jersey; and. 10. Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia Department of Medicine, University of Melbourne, Melbourne, Australia andrew.scott@onjcri.org.au.
Abstract
UNLABELLED: Subtype A2 of the erythropoietin-producing hepatocellular tyrosine kinase (EphA2) cell surface receptor is expressed in a range of epithelial cancers. This study evaluated the molecular imaging of EphA2 expression in vivo in mouse tumor models using SPECT/MR and PET/MR and a humanized anti-EphA2 antibody, DS-8895a. METHODS: DS-8895a was labeled with (111)In, (125)I, and (89)Zr and assessed for radiochemical purity, immunoreactivity (Lindmo analysis), antigen-binding affinity (Scatchard analysis), and serum stability in vitro. In vivo biodistribution, imaging, and pharmacokinetic studies were performed with SPECT/MR and PET/MR. A dose-escalation study was also performed to determine EphA2 receptor saturability through tissue and imaging quantitative analysis. RESULTS: All conjugates demonstrated good serum stability and specific binding to EphA2-expressing cells in vitro. In vivo biodistribution studies showed high uptake of (111)In-CHX-A″-DTPA-DS-8895a and (89)Zr-Df-Bz-NCS-DS-8895a in EphA2-expressing xenograft models, with no specific uptake in normal tissues. In comparison, retention of (125)I-DS-8895a in tumors was lower because of internalization of the radioconjugate and dehalogenation. These results were confirmed by SPECT/MR and PET/MR. EphA2 receptor saturation was observed at the 30 mg/kg dose. CONCLUSION: Molecular imaging of tumor uptake of DS-8895a allows noninvasive measurement of EphA2 expression in tumors in vivo and determination of receptor saturation. (89)Zr-Df-Bz-NCS-DS-8895a is suited for human bioimaging trials on the basis of superior imaging characteristics and will inform DS-8895a dose assessment and patient response evaluation in clinical trials.
UNLABELLED: Subtype A2 of the erythropoietin-producing hepatocellular tyrosine kinase (EphA2) cell surface receptor is expressed in a range of epithelial cancers. This study evaluated the molecular imaging of EphA2 expression in vivo in mousetumor models using SPECT/MR and PET/MR and a humanized anti-EphA2 antibody, DS-8895a. METHODS:DS-8895a was labeled with (111)In, (125)I, and (89)Zr and assessed for radiochemical purity, immunoreactivity (Lindmo analysis), antigen-binding affinity (Scatchard analysis), and serum stability in vitro. In vivo biodistribution, imaging, and pharmacokinetic studies were performed with SPECT/MR and PET/MR. A dose-escalation study was also performed to determine EphA2 receptor saturability through tissue and imaging quantitative analysis. RESULTS: All conjugates demonstrated good serum stability and specific binding to EphA2-expressing cells in vitro. In vivo biodistribution studies showed high uptake of (111)In-CHX-A″-DTPA-DS-8895a and (89)Zr-Df-Bz-NCS-DS-8895a in EphA2-expressing xenograft models, with no specific uptake in normal tissues. In comparison, retention of (125)I-DS-8895a in tumors was lower because of internalization of the radioconjugate and dehalogenation. These results were confirmed by SPECT/MR and PET/MR. EphA2 receptor saturation was observed at the 30 mg/kg dose. CONCLUSION: Molecular imaging of tumor uptake of DS-8895a allows noninvasive measurement of EphA2 expression in tumors in vivo and determination of receptor saturation. (89)Zr-Df-Bz-NCS-DS-8895a is suited for human bioimaging trials on the basis of superior imaging characteristics and will inform DS-8895a dose assessment and patient response evaluation in clinical trials.
Authors: Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott Journal: AAPS J Date: 2018-03-08 Impact factor: 4.009
Authors: Tran T Hoang; Komal Mandleywala; Tara Viray; Kel Vin Tan; Jason S Lewis; Patricia M R Pereira Journal: Mol Imaging Biol Date: 2022-02-11 Impact factor: 3.484
Authors: Ingrid Julienne Georgette Burvenich; Sagun Parakh; Fook-Thean Lee; Nancy Guo; Zhanqi Liu; Hui Kong Gan; Angela Rigopoulos; Graeme Joseph O'Keefe; Sylvia Jie Gong; Yit Wooi Goh; Henri Tochon-Danguy; Fiona Elizabeth Scott; Masakatsu Kotsuma; Kenji Hirotani; Giorgio Senaldi; Andrew Mark Scott Journal: Theranostics Date: 2018-07-30 Impact factor: 11.556
Authors: Thomas Kryza; Tashbib Khan; Simon Puttick; Chao Li; Kamil A Sokolowski; Brian Wc Tse; Tahleesa Cuda; Nicholas Lyons; Madeline Gough; Julia Yin; Ashleigh Parkin; Elena I Deryugina; James P Quigley; Ruby H P Law; James C Whisstock; Andrew D Riddell; Andrew P Barbour; David K Wyld; Paul A Thomas; Stephen Rose; Cameron E Snell; Marina Pajic; Yaowu He; John D Hooper Journal: Theranostics Date: 2020-03-04 Impact factor: 11.556
Authors: Julie Bolcaen; Shankari Nair; Cathryn H S Driver; Tebatso M G Boshomane; Thomas Ebenhan; Charlot Vandevoorde Journal: Pharmaceuticals (Basel) Date: 2021-06-29